Product Description
Mechanisms of Action: TLR2 Inhibitor,TLR4 Inhibitor,TLR7 Inhibitor,TLR8 Inhibitor,TLR9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | India | Italy | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Spain | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Huahai Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Russia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Cholecystitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GIB-01-02-2023 | P1 |
Recruiting |
Cholecystitis |
2024-12-31 |
21% |